SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (2489)8/27/2005 10:00:27 AM
From: Biotech Jim  Read Replies (1) | Respond to of 3044
 
mogcpy-

I find it interesting that there is potential concern over the situation of Revlimid at the FDA, by options investors. I do not hold Celgene, but wish I had. It ahs had a tremendous run. If the drug has an approval delay, I will be buying CELG. There is anticipation at CELG that it will be a billion dollar drug, and they are looking for ways to spend the profits. CELG will also be a strong buyout candidate after R approval, IMHO.

BJ


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News